Jamjoom Pharma profit up 71% to SAR 292.4M in 2023; Q4 at SAR 44.5M

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 292.4 million in 2023, leaping 71% from SAR 171.3 million a year earlier.

Financials (M)

Item	2022	2023	Change‬
Revenues	916.67	1,100.82	20.1 %
Gross Income	593.92	703.79	18.5 %
Operating Income	233.33	313.38	34.3 %
Net Income	171.31	292.40	70.7 %
Average Shares	70.00	70.00	-
EPS (Riyals)	2.45	4.18	70.7 %

The profit increase was buoyed by a 20.1% year-on-year (YoY) revenue increase and a decline in finance costs by 96% YoY. Selling and distribution (S&D) expenses rose 9.7% but the growth rate remained lower than the rise in revenue.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2022	Q4 2023	Change‬
Revenues	196.84	207.86	5.6 %
Gross Income	125.41	118.86	(5.2 %)
Operating Income	38.26	42.24	10.4 %
Net Income	31.76	44.48	40.1 %
Average Shares	70.00	70.00	-
EPS (Riyals)	0.45	0.64	40.1 %

Item	Q3 2023	Q4 2023	Change‬
Revenues	292.61	207.86	(29.0 %)
Gross Income	187.23	118.86	(36.5 %)
Operating Income	84.67	42.24	(50.1 %)
Net Income	77.25	44.48	(42.4 %)
Average Shares	70.00	70.00	-
EPS (Riyals)	1.10	0.64	(42.4 %)

The fourth-quarter earnings leapt 40% to SAR 44.5 million, compared to SAR 31.76 million in the year-ago period.

On a quarterly basis, the company posted a 42.4% decline in Q4 profit from SAR 77.25 million in Q3.

Shareholders’ equity, no minority interest, increased to SAR 1.40 billion as of Dec. 31, 2023, compared to SAR 1.21 billion a year earlier.

Attached Document:

View more financial results

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

	Current
Market Cap (M Riyal)	10,990.00
Enterprise Value (EV) (M)	10,868.18
Shares Outstanding ((M))	70.00
EPS ( Riyal) (TTM)	4.99
Book Value (BV) ( Riyal)	20.64
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	31.45
P/E (TTM)	31.45
Price/book	7.61
Return on Average Assets (%) (TTM)	19.9
Return on Average Equity (%) (TTM)	24.9

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	701.30	-	442.77	-	171.70	-
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
Q1 2021	121.82	-	77.37	-	14.74	-
Q2 2021	193.05	-	124.75	-	49.73	-
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
Q1 2022	243.78	100.1 %	164.32	112.4 %	77.42	425.2 %
Q2 2022	238.30	23.4 %	153.06	22.7 %	57.61	15.9 %
Q3 2022	237.76	-	151.13	-	60.03	-
Q4 2022	196.84	-	125.41	-	38.26	-
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
Q1 2023	300.85	23.4 %	199.61	21.5 %	93.91	21.3 %
Q2 2023	298.40	25.2 %	198.10	29.4 %	92.56	60.7 %
Q3 2023	292.61	23.1 %	187.23	23.9 %	84.67	41.1 %
Q4 2023	207.86	5.6 %	118.86	(5.2 %)	42.24	10.4 %
2023	1,100.82	20.1 %	703.79	18.5 %	313.38	34.3 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	-	-	-	-	-	-
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	701.30	-	442.77	-	171.70	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
2023	1,100.82	20.1 %	703.79	18.5 %	313.38	34.3 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	150.84	-	2.15	-	150.84	2.15
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	159.93	6.0 %	2.28	-	159.93	2.28
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	206.86	29.3 %	2.96	-	206.86	2.96
Q1 2021	10.98	-	0.16	-	10.98	0.16
Q2 2021	41.19	-	0.59	-	41.19	0.59
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
Q1 2022	43.53	296.3 %	0.62	(28.75)	72.28	1.03
Q2 2022	50.42	22.4 %	0.72	(4.27)	54.69	0.78
Q3 2022	45.60	-	0.65	(7.96)	53.56	0.77
Q4 2022	31.76	-	0.45	(6.98)	38.73	0.55
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
Q1 2023	84.40	93.9 %	1.21	-	84.40	1.21
Q2 2023	86.27	71.1 %	1.23	-	86.27	1.23
Q3 2023	77.25	69.4 %	1.10	-	77.25	1.10
Q4 2023	44.48	40.1 %	0.64	-	44.48	0.64
2023	292.40	70.7 %	4.18	-	292.40	4.18

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	-	-	-	-	-	-
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	150.84	-	2.15	-	150.84	2.15
2019	159.93	6.0 %	2.28	-	159.93	2.28
2020	206.86	29.3 %	2.96	-	206.86	2.96
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
2023	292.40	70.7 %	4.18	-	292.40	4.18

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
2018	63.14 %	30.54 %	21.51 %
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
2019	57.72 %	29.63 %	21.86 %
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
2020	63.74 %	33.74 %	25.69 %
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
2021	64.52 %	28.43 %	23.20 %
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	64.79 %	28.15 %	23.92 %
2022	64.79 %	28.15 %	23.92 %
Q1 2023	64.62 %	28.21 %	23.76 %
Q2 2023	65.22 %	29.98 %	25.44 %
Q3 2023	65.25 %	30.78 %	26.33 %
Q4 2023	64.00 %	30.92 %	26.59 %
2023	63.93 %	30.89 %	26.56 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	63.14 %	30.54 %	21.51 %
2019	57.72 %	29.63 %	21.86 %
2020	63.74 %	33.74 %	25.69 %
2021	64.52 %	28.43 %	23.20 %
2022	64.79 %	28.15 %	23.92 %
2023	63.93 %	30.89 %	26.56 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	63.51 %	-	9.02 %
Q2 2021	64.62 %	32.15 %	21.34 %
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	67.40 %	34.26 %	29.65 %
Q2 2022	64.23 %	26.75 %	22.95 %
Q3 2022	63.56 %	27.86 %	22.53 %
Q4 2022	63.71 %	22.63 %	19.68 %
Q1 2023	66.35 %	33.30 %	28.05 %
Q2 2023	66.39 %	33.17 %	28.91 %
Q3 2023	63.98 %	31.24 %	26.40 %
Q4 2023	57.18 %	23.79 %	21.40 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2014	-	-	-	-
Q2 2014	-	-	-	-
Q3 2014	-	-	-	-
Q4 2014	-	-	-	-
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	-	-	-	-
Q2 2018	-	-	-	-
Q3 2018	-	-	-	-
Q4 2018	-	-	-	-
Q1 2019	-	-	-	-
Q2 2019	-	-	-	-
Q3 2019	-	-	-	-
Q4 2019	-	-	-	-
Q1 2020	-	-	-	-
Q2 2020	-	-	-	-
Q3 2020	-	-	-	-
Q4 2020	-	-	-	-
Q1 2021	70.00	-	-	-
Q2 2021	70.00	-	-	16.98
Q3 2021	-	-	-	-
Q4 2021	-	-	-	-
Q1 2022	70.00	-	-	17.67
Q2 2022	70.00	-	-	18.03
Q3 2022	70.00	-	-	18.34
Q4 2022	70.00	2.45	3.13	17.38
Q1 2023	70.00	3.03	3.31	18.13
Q2 2023	70.00	3.54	3.76	19.36
Q3 2023	70.00	4.00	4.09	19.45
Q4 2023	70.00	4.18	4.18	20.06

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	-	-	-	-
2015	-	-	-	-
2016	-	-	-	-
2017	-	-	-	-
2018	70.00	2.15	2.15	14.28
2019	70.00	2.28	2.28	15.28
2020	70.00	2.96	2.96	16.84
2021	70.00	2.44	2.44	17.59
2022	70.00	2.45	3.13	17.38
2023	70.00	4.18	4.18	20.06

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	-	-	-
Q1 2023	-	-	-
Q2 2023	25.26	23.82	4.62
Q3 2023	28.98	28.28	5.95
Q4 2023	27.53	27.53	5.73

Period	P/E	Adjusted P/E	Price/book
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	-	-	-
2021	-	-	-
2022	-	-	-
2023	27.53	27.53	5.73

Business Segments (Million)

Compared With The

Period	Pharmaceutical products	Consumer Health Products
Q1 2021	107.12	14.70
Q2 2021	174.82	18.23
Q1 2022	203.09	40.70
Q2 2022	207.60	30.70
Q3 2022	206.65	31.11
Q4 2022	180.05	16.79
Q1 2023	258.50	42.35
Q2 2023	256.14	42.26
Q3 2023	251.49	41.12
Q4 2023	189.49	18.36

Period	Pharmaceutical products	Consumer Health Products
2020	731.16	74.15
2021	663.46	72.22
2022	797.38	119.30
2023	956.73	144.09

Analysts Estimates (Million)

Item	Q4 2023 (e)	Q4 2023 (a)	Change‬
Average	44.67	44.48	(0.4 %)

Estimates vs Actual (Million)

Item	Q4 2023 (e)	Q4 2023 (a)	Change
Al Rajhi Capital	40.00	44.48	11.2 %
GIB Capital	40.00	44.48	11.2 %
United Securities Company	54.00	44.48	(17.6) %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Jamjoom Pharma profit up 71% to SAR 292.4M in 2023; Q4 at SAR 44.5M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2023 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Jamjoom Pharma profit up 71% to SAR 292.4M in 2023; Q4 at SAR 44.5M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2023

Revenue by Business Segment (Latest) 2023 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)